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This is anSickle Cell Disease
A Continued Call to Action
Kathryn L. Hassell, MDOne of the challenges facing the U.S. healthcaresystem is the ability to comprehensively servethose with relatively rare and complex disorders,
particularly for those conditions that most impact com-
munities that are historically disadvantaged and under-
served. Such a condition is sickle cell disease (SCD), an
inherited blood disorder that results in a lifetime of
anemia, severe episodes of pain, and childhood onset of
acute and chronic organ damage that progresses in
adulthood, leading to premature mortality.1 Affecting an
estimated 100,000 Americans,2 the majority are from
African American and Hispanic communities and rely
heavily on public insurance and healthcare programs.3
Because SCD was ﬁrst described in the U.S. in 1910,
research has elucidated interventions that can signiﬁcantly
improve the course of the disease. Prevention of invasive
pneumococcal infection with the use of prophylactic
penicillin and vaccination can markedly reduce infant
and early childhood mortality,2,4 which serves as justiﬁca-
tion for the now-universal newborn screening for sickle cell
anemia (SCA) across the U.S. Reduction in the risk of
stroke, whichmay afﬂict up to 10% of children with SCA, is
possible with the institution of transfusion5 or hydroxyurea
therapy6 after identifying the children most at risk using
routine transcranial Doppler screening.7 Hydroxyurea, an
oral agent chemotherapy agent, has been shown to reduce
acute pain episodes in infants and adults8,9 and may extend
life expectancy in adults10; it is the only U.S. Food and
Drug Administration–approved drug for the treatment of
SCD. A growing number of new drug therapies are under
study,11 stem cell (bone marrow) transplantation is poten-
tially curative for individuals with a matched donor,12 and
human gene therapy experiments are under way13.
However, the promise of these and future therapies
can only be realized if individuals with SCD have access
to a system that is able to provide coordinated care byivision of Hematology, Colorado Sickle Cell Treatment and
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tine health care across the life span. An organized system
of care, as provided to those living with cystic ﬁbrosis and
hemophilia, does not exist for SCD. Mounting evidence14–16
suggests that therapies of proven beneﬁt, including
prophylactic penicillin, transcranial Doppler, and hydro-
xyurea therapy, are not being utilized.
In recognition of disparities involving SCD, the
American Society of Pediatric Hematology and Oncology
convened a Sickle Cell Summit in June 2007.17 The
premise and vision of the Summit was as follows:
An adequately funded, coordinated, comprehensive,
and integrated national model for care of persons with
SCD, involving all stake holders, will lead to improved
outcomes for all Americans with the disease; lay the
foundation for conducting health services, outcomes, and
clinical/translational/basic research; and ultimately
improve outcomes of future persons globally with SCD.
With this in mind, participants from major federal
funding and healthcare policy agencies, foundations, pro-
fessional societies, community organizations, patients, and
expert clinicians and researchers built consensus around
goals and opportunities for bridging the gaps between this
vision and the apparent reality, acknowledging that data
regarding the status of health care and outcomes for those
living with SCD were poorly deﬁned; the number and
characteristics of affected individuals have not been deﬁni-
tively determined. Five major goals were identiﬁed:1.ier
//crspeaking with a uniﬁed voice to make a clear case
statement;2. access to care from knowledgeable healthcare provi-
ders in a patient-centered medical home;3. population-based surveillance to measure outcomes;
4. basic, clinical, translational, and health services
research; and
5. enhanced role of the community.
The papers in this supplement to the American Journal of
Preventive Medicine highlight some of the progress made
since the Summit in these targeted areas through activities
sponsored by DHHS agencies, including the Centers for
Disease Control and Prevention (CDC), Health Resources
and Services Administration, and NIH. A unifying theme
of the supplement is the initial assessment of the state
of health care for those living with SCD and the uptakeInc.
eativecommons.org/licenses/by-nc-nd/4.0/).
Am J Prev Med 2016;51(1S1):S1–S2 S1
Hassell / Am J Prev Med 2016;51(1S1):S1–S2S2of management strategies with proven beneﬁt, including
vaccination against pneumococcal infection, transcranial
Doppler screening, and initiation of hydroxyurea therapy.
Data from the Registries and Surveillance System for
Hemoglobinopathies program,18 cosponsored by CDC and
NIH, as well as utilization of state-based administrative data
sets, can reveal population-based patterns of utilization that
may target areas for improvement. At a more granular level,
exploration of the impact of care coordination strategies,
health information technologies, and use of quality improve-
ment methodologies within speciﬁc clinical practices offer
guidance to optimization of scalable approaches that lead to
an increase in adherence to recommended screening,
prevention, and treatment strategies. Successful clinical
research requires an understanding of potential barriers to
participation. Exploring the role of newborn screening and
public health programs, as well as demonstrating the
beneﬁts of community health workers, offers the opportu-
nity of supporting individuals and their families beyond the
medical facility. In particular, this may represent a key
component to comprehensive patient-centered care, espe-
cially in culturally and geographically isolated areas of the
U.S. as well as in other countries with a much larger disease
burden and even more–limited healthcare resources.
The work described in this supplement demonstrates
an increasing capacity to better understand the landscape
of health care for those living with SCD, informing
understanding of the current implementation of interven-
tions and the potential to capture and monitor health
outcomes. This represents important progress since the
American Society of Pediatric Hematology and Oncology
Summit 8 years ago. Even as these papers conﬁrm the
continued inconsistent utilization of proven therapies and
ongoing struggles with management of acute and chronic
complications, mechanisms of improvement are proposed
and preliminarily explored. Reﬁnement of these strategies
and data are needed to further demonstrate how care
coordination strategies, improvement in adherence to
guidelines, and implementation of a broader community
base of support will translate into improved outcomes.
Continued support for this development through DHHS,
in collaboration with providers, those living with sickle cell
and their communities, and identiﬁcation of resources
within the evolving healthcare system will be necessary to
sustain identiﬁed successes. And so, the “call to action”
made at the American Society of Pediatric Hematology
and Oncology Summit remains loud and clear today.
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